Department of Surgery, Mount Sinai Health System, 1 Gustave L. Levy Place, New York, NY, 10029, USA.
Department of Cardiology, Mount Sinai Health System, New York, USA.
Surg Endosc. 2023 Nov;37(11):8655-8662. doi: 10.1007/s00464-023-10264-x. Epub 2023 Jul 26.
Patients suffering from advanced heart failure may undergo left ventricular assist device (LVAD) placement as a bridge to cardiac transplantation. However, those with a BMI above 35 kg/m are generally not considered eligible for transplant due to their elevated cardiac risk. We review our experience with bariatric surgery in this high-risk population to assess its safety and efficacy in reducing BMI to permit cardiac transplantation.
We retrospectively reviewed all patients on durable LVAD support who underwent sleeve gastrectomy (SG) at Mount Sinai Hospital between August 2018 and December 2022. Electronic medical records were reviewed to analyze patient demographics, surgical details, and outcomes regarding weight loss and heart transplantation.
We identified twelve LVAD patients who underwent SG. Three were performed laparoscopically and 9 via robotic approach. Four patients (33.3%) underwent an orthotopic heart transplant (OHTx). Half of these patients were female. For patients who underwent OHTx, mean age at LVAD placement was 41.0 (R30.6-52.2), at SG was 43.9 (R32.7-55.0) and at OHTx was 45.3 years (R33.3-56.8). Mean BMI increased from 38.8 at LVAD placement to 42.5 prior to SG. Mean time from SG to OHTx was 17.9 months (R6-7-27.5) during which BMI decreased to mean 32.8 at the time of OHTx. At most recent follow-up, mean BMI was 31.9. All patients were anticoagulated prior to surgery; one required return to the operating room on post-operative day 1 after SG for bleeding and one was re-admitted on post-operative day 7 for hematochezia treated conservatively.
SG is a safe and effective operation in patients with severe obesity and heart failure requiring an LVAD. 66.7% of our cohort achieved target BMI < 35 and 33.3% underwent heart transplantation. Longer term follow-up is needed to clarify full bridge-to-transplant rate and long-term survival outcomes.
患有晚期心力衰竭的患者可能需要接受左心室辅助装置(LVAD)植入作为心脏移植的桥接治疗。然而,由于心脏风险增加,BMI 高于 35kg/m 的患者通常不符合移植条件。我们回顾了在这一高危人群中接受减重手术的经验,以评估其安全性和有效性,即通过减轻体重使 BMI 降低至可接受的范围,从而实现心脏移植。
我们回顾性分析了 2018 年 8 月至 2022 年 12 月期间在西奈山医院接受持久 LVAD 支持的所有接受袖状胃切除术(SG)的患者。对电子病历进行了回顾,以分析体重减轻和心脏移植的患者人口统计学、手术细节和结果。
我们确定了 12 名接受 SG 的 LVAD 患者。其中 3 例为腹腔镜手术,9 例为机器人辅助手术。4 名患者(33.3%)接受了原位心脏移植(OHTx)。这些患者中有一半是女性。接受 OHTx 的患者中,LVAD 植入时的平均年龄为 41.0(R30.6-52.2),SG 时为 43.9(R32.7-55.0),OHTx 时为 45.3 岁(R33.3-56.8)。LVAD 植入时的 BMI 均值为 38.8,SG 前增至 42.5,SG 至 OHTx 的平均时间为 17.9 个月(R6-7-27.5),在此期间 BMI 降至 OHTx 时的均值 32.8。在最近的随访中,BMI 的均值为 31.9。所有患者在手术前均接受抗凝治疗;1 例患者在 SG 后第 1 天因出血需要返回手术室,1 例患者在第 7 天因保守治疗的血便再次入院。
SG 是一种安全有效的手术,适用于需要 LVAD 的严重肥胖和心力衰竭患者。我们的队列中有 66.7%的患者达到了目标 BMI<35,33.3%的患者接受了心脏移植。需要更长时间的随访来明确完全桥接移植率和长期生存结果。